Mark S. Huberman

6.6k citations
80 papers · 4.6k · 4 hit papers · h-index 30

Impact in

    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
  • Oncology top 1%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • HER2/EGFR in Cancer Research

Papers in

Mark S. Huberman

79 papers receiving 4.5k citations

Mark S. Huberman's Hit Papers

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers 2015 · 362 citations
3620+7+14Years since publication250500750

Peers

Mark S. Huberman
Comparison fields: 5 of 95
  • Pulmonary and Respiratory Medicine 2.9k
  • Oncology 2.1k
  • Cancer Research 517
  • Hepatology 165
  • Dermatology 162
Replace Bilal Piperdi with:
Bilal Piperdi United States
Dimitrios Bafaloukos Greece
Mircea Dediu Romania
Takeshi Horai Japan
Gaia Schiavon United Kingdom
Renato Martins United States
M. Mueser France
Ihor Vynnychenko Ukraine
Maximiliano Van Kooten Argentina
David A. Ramies United States
Mark S. Huberman relative to Bilal Piperdi United States Bilal Piperdi's profile →
Citations per field
00.5×1.5×1.8×
Bilal Piperdi · 1×
Citations per year

Countries citing papers authored by Mark S. Huberman

Since Specialization
Citations

This map shows the geographic impact of Mark S. Huberman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Huberman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Huberman more than expected).

Fields of papers citing papers by Mark S. Huberman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Huberman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Huberman. The network helps show where Mark S. Huberman may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark S. Huberman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark S. Huberman Line = papers co-authored together Mark S. Huberman links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 80 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
Hit paper breakdown →
2004893
2
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
Hit paper breakdown →
2006492
3
BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
Hit paper breakdown →
2007409
4
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Hit paper breakdown →
2015362
5 2012172
6 2008139
7 2017139
8 2007137
9 2014120
10 1980119
11 2017106
12 199782
13 199874
14 200874
15 201870
16 201870
17 201066
18 201563
19 201360
20 201851

About Mark S. Huberman

Mark S. Huberman is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Surgery and Epidemiology, having authored 80 papers that have together received 4.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (13 papers), Lung Cancer Diagnosis and Treatment (13 papers), Cancer Genomics and Diagnostics (6 papers), Cancer therapeutics and mechanisms (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and Neuroendocrine Tumor Research Advances (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.9k citations), Oncology (2.1k citations), Cancer Research (517 citations), Hepatology (165 citations) and Dermatology (162 citations). Mark S. Huberman has collaborated with scholars based in United States, Israel and Canada. Frequent co-authors include Daniel B. Costa, Susumu Kobayashi, Paul A. VanderLaan, Daniel G. Tenen, Deepa Rangachari, Balázs Halmos, Eric K. Rowinsky, Daniel D. Karp, P. Santabárbara and Philip Bonomi. Their work appears in journals such as Journal of Thoracic Oncology, Lung Cancer, Journal of Clinical Oncology, Cancer and Clinical Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact